Get the Stockscreener App
122.09
2.39%
-2.99
After Hours:
122.10
0.010
+0.01%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $122.09, with a volume of 6.38M.
It is down -2.39% in the last 24 hours and down -3.38% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$125.08
Open:
$124.62
24h Volume:
6.38M
Relative Volume:
1.04
Market Cap:
$212.30B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.31
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-4.62%
1M Performance:
-3.38%
6M Performance:
-8.60%
1Y Performance:
+5.61%
1-Day Range:
$121.71
$124.62
1-Week Range:
$121.71
$128.99
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
122.09 | 217.50B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
93.84 | 144.57B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.60 | 139.21B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.26 | 129.94B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.32 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott (ABT) Expands Lingo Glucose Monitor to Android Users - GuruFocus
Abbott (NYSE: ABT) adds Lingo to Android, cites 15% lower odds of glucose spikes - Stock Titan
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump - 24/7 Wall St.
SVB Wealth LLC Has $12.17 Million Stake in Abbott Laboratories $ABT - MarketBeat
Divergent Views Emerge on Abbott Laboratories’ Stock Valuation - AD HOC NEWS
The Minnesotan behind Cologuard, which fueled the biggest health care acquisition of 2025 - Star Tribune
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives - Finviz
Abbott (ABT) awards $1 million as Big Ten drive logs 83,043 blood donations - Stock Titan
Seaview Investment Managers LLC Purchases New Stake in Abbott Laboratories $ABT - MarketBeat
UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition - MSN
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Is Abbott Laboratories Fairly Priced After Growth In Devices And Diagnostics? - Yahoo Finance
FDA Warning For Abbott Glucose Sensors After 700 Injuries, 7 DeathsAbbott Laboratories (NYSE:ABT) - Benzinga
Guggenheim Capital LLC Buys 11,794 Shares of Abbott Laboratories $ABT - MarketBeat
Assessing Abbott After 10.5% Gains and DCF PE Signals Amid Exact Sciences Deal Talk - simplywall.st
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley - Yahoo Finance
Arrowstreet Capital Limited Partnership Purchases 291,987 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Diabetes Glucose Monitors Recalled After 7 Deaths and More Than 700 Injuries - People.com
Top Analyst Reports for HSBC, Abbott & Shell - Yahoo Finance
Medtronic launches new diabetes tech integrated with Abbott sensor - Cardiovascular Business
FDA Issues Warning on Abbott (ABT) Glucose Monitors After Reported Deaths - GuruFocus
How Abbott Laboratories (ABL) stock trades after rate cuts2025 Trade Ideas & Fast Exit and Entry Trade Guides - Newser
Faulty Glucose Monitor Sensors May Be Tied to 7 Deaths, F.D.A. Says - The New York Times
Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - marketscreener.com
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and MoreResearchAndMarkets.com - The AI Journal
Muscles, the New Flex: Abbott Launches Two New Ensure Max Protein Shakes to Tap into Growing Muscle Health Movement - Finviz
Abbott (NYSE: ABT) debuts Ensure Max Protein 42g, 2 in 1 shakes with Walmart rollout - Stock Titan
Millions of Abbott Glucose Sensors Recalled After Faulty Readings Linked to Deaths - The Suburban
Abbott - The Pharma Letter
Don't Ignore The Insider Selling In Abbott Laboratories - simplywall.st
Abbott Laboratories $ABT Stake Lifted by First Trust Advisors LP - MarketBeat
Baird Financial Group Inc. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Medtronic launches insulin delivery system with Abbott-made sensor - MedTech Dive
Abbott Laboratories' (NYSE:ABT) Price Is Right But Growth Is Lacking - 富途牛牛
Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups - USA Herald
Abbott Defends Glucose Monitor Patents In Sinocare Fight - Law360
Abbott Laboratories (NYSE: ABT) sees Vanguard report 10.05% beneficial stake - Stock Titan
The US Rollout of MiniMed 780G With Abbott's Sensor May Lift MDT Stock - sharewise.com
7 deaths, hundreds of injuries may be linked to diabetes glucose monitor errors, FDA says - CBS News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
M&T Bank Corp Trims Stake in Abbott Laboratories $ABT - MarketBeat
Shelton Capital Management Has $8.97 Million Stake in Abbott Laboratories $ABT - MarketBeat
Loomis Sayles & Co. L P Raises Position in Abbott Laboratories $ABT - MarketBeat
Can Abbott Laboratories stock weather global recessionForecast Cut & AI Based Buy and Sell Signals - Newser
Invesco Ltd. Increases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
States Hit Abbott With FCA Suit Over Infant Formula Recall - Law360
7 deaths linked to faulty blood glucose monitors as FDA issues safety warning - Fox Business
Seven deaths linked to malfunctioning glucose monitors - USA Today
Medtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott - Medtronic
Smith Moore & CO. Has $3.40 Million Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):